Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 in Narcolepsy Type 1
NCT07363720Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Started Jan 2026; status: active, not recruiting.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT07363720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363720.